CorMedix (CRMD) Competitors $13.54 +0.02 (+0.13%) Closing price 03:59 PM EasternExtended Trading$13.54 +0.00 (+0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRMD vs. HCM, RARE, XENE, CRNX, ALVO, IMVT, GMTX, BHC, KYMR, and KNSAShould you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Xenon Pharmaceuticals (XENE), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Gemini Therapeutics (GMTX), Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. CorMedix vs. Its Competitors HUTCHMED Ultragenyx Pharmaceutical Xenon Pharmaceuticals Crinetics Pharmaceuticals Alvotech Immunovant Gemini Therapeutics Bausch Health Cos Kymera Therapeutics Kiniksa Pharmaceuticals International CorMedix (NASDAQ:CRMD) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Does the media favor CRMD or HCM? In the previous week, HUTCHMED had 3 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for HUTCHMED and 0 mentions for CorMedix. CorMedix's average media sentiment score of 0.57 beat HUTCHMED's score of -0.03 indicating that CorMedix is being referred to more favorably in the media. Company Overall Sentiment CorMedix Positive HUTCHMED Neutral Is CRMD or HCM more profitable? CorMedix has a net margin of 42.11% compared to HUTCHMED's net margin of 0.00%. CorMedix's return on equity of 42.73% beat HUTCHMED's return on equity.Company Net Margins Return on Equity Return on Assets CorMedix42.11% 42.73% 34.19% HUTCHMED N/A N/A N/A Do analysts rate CRMD or HCM? CorMedix presently has a consensus target price of $16.71, suggesting a potential upside of 23.46%. HUTCHMED has a consensus target price of $28.00, suggesting a potential upside of 73.81%. Given HUTCHMED's stronger consensus rating and higher possible upside, analysts clearly believe HUTCHMED is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88HUTCHMED 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in CRMD or HCM? 34.2% of CorMedix shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 5.3% of CorMedix shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, CRMD or HCM? HUTCHMED has higher revenue and earnings than CorMedix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M23.25-$17.93M$0.7518.05HUTCHMED$630.20M4.46$37.73MN/AN/A Which has more risk and volatility, CRMD or HCM? CorMedix has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. SummaryCorMedix beats HUTCHMED on 9 of the 14 factors compared between the two stocks. Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRMD vs. The Competition Export to ExcelMetricCorMedixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.07%P/E Ratio18.0520.3730.4325.14Price / Sales23.25238.33392.4187.63Price / CashN/A42.3737.0358.50Price / Book4.577.918.956.21Net Income-$17.93M-$54.72M$3.26B$265.38M7 Day Performance7.36%1.58%1.03%-1.12%1 Month Performance23.75%5.81%4.28%-0.68%1 Year Performance170.22%8.71%28.38%18.92% CorMedix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRMDCorMedix2.2586 of 5 stars$13.54+0.1%$16.71+23.5%+169.3%$1.01B$43.47M18.0530HCMHUTCHMED2.6791 of 5 stars$15.48+3.2%$28.00+80.9%-11.6%$2.70B$630.20M0.001,811RAREUltragenyx Pharmaceutical4.6402 of 5 stars$27.39-0.5%$81.50+197.6%-44.6%$2.64B$560.23M-4.951,294XENEXenon Pharmaceuticals2.0502 of 5 stars$34.11+2.0%$54.33+59.3%-4.7%$2.62B$9.43M-10.56210Options VolumeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.5231 of 5 stars$27.38+2.0%$68.86+151.5%-46.0%$2.58B$1.04M-6.66210News CoverageALVOAlvotech2.6006 of 5 stars$8.52+0.7%$14.00+64.3%-35.0%$2.57B$585.60M23.031,032Trending NewsAnalyst DowngradeShort Interest ↓IMVTImmunovant2.9164 of 5 stars$14.76-4.5%$35.33+139.4%-53.0%$2.52BN/A-5.39120GMTXGemini TherapeuticsN/A$58.03+1.7%N/A+16.5%$2.51BN/A-58.0330BHCBausch Health Cos4.3097 of 5 stars$6.68+16.1%$9.00+34.8%+30.3%$2.47B$9.63B25.6820,700Positive NewsHigh Trading VolumeKYMRKymera Therapeutics3.0233 of 5 stars$37.68-7.2%$59.11+56.9%-8.9%$2.45B$47.07M-12.15170High Trading VolumeKNSAKiniksa Pharmaceuticals International2.4271 of 5 stars$32.74+1.8%$41.17+25.7%+26.1%$2.43B$423.24M818.70220Insider Trade Related Companies and Tools Related Companies HCM Alternatives RARE Alternatives XENE Alternatives CRNX Alternatives ALVO Alternatives IMVT Alternatives GMTX Alternatives BHC Alternatives KYMR Alternatives KNSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRMD) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access